Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
Status:
Recruiting
Trial end date:
2023-11-23
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, two arm, parallel group, proof-of-concept, non-confirmatory
study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with
membranous nephropathy (MN) who are at high risk of disease progression defined on the basis
of antibody anti-PLA2R titre and proteinuria.